Efficacy and Tolerability of Intranasal Fentanyl Spray in Cancer Patients with Breakthrough Pain

Clinical Therapeutics

Volumn 37, Issue 3, 2015, Pages 585-596

  Thronæs, Morten ^a,b   Popper, Lars ^c   Eeg, Martin ^c   Jaatun, Ellen ^a,b   Kvitberg, Magnar ^d   Kaasa, Stein ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^d Drammen Hosp   (Norway)

Author keywords

breakthroughpain; cross overefficacy phase; Instanyl; intranasalfentanylspray; paininten sity difference.

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; BREAKTHROUGH PAIN; CHEMICALLY INDUCED; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN MEASUREMENT;

EID: 84939999752     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.12.010     Document Type: Article

References (30)

1. M.H. van den Beuken-van Everdingen, J.M. de Rijke, and A.G. Kessels Prevalence of pain in patients with cancer: a systematic review of the past 40 years Ann Oncol 18 2007 1437 1449
2. A. Caraceni, G. Hanks, and S. Kaasa Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC Lancet Oncol 13 2012 e58 e68
3. R.K. Portenoy, and N.A. Hagen Breakthrough pain: definition and management Oncology (Williston Park) 3 8 Suppl 1989 25 29
4. S. Deandrea, O. Corli, and D. Consonni Prevalence of Breakthrough Cancer Pain: A Systematic Review and a Pooled Analysis of Published Literature J Pain Symptom Manage 47 2014 57 76
5. A. Davies, A. Buchanan, and G. Zeppetella Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients J Pain Symptom Manage 47 2014 57 76
6. S.L. Collins, C.C. Faura, R.A. Moore, and H.J. McQuay Peak plasma concentrations after oral morphine: a systematic review J Pain Symptom Manage 16 6 1998 388 402
7. S. Mercadante Managing breakthrough pain Curr Pain Headache Rep 15 2011 244 249
8. H. Smith A comprehensive review of rapid-onset opioids for breakthrough pain CNS Drugs 26 2012 509 535
9. Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A Network Meta-Analysis of the Efficacy of Opioid Analgesics for the Management of Breakthrough Cancer Pain Episodes. J Pain Symptom Manage. 47:772-785.e5.
10. O. Dale, R. Hjortkjaer, and E.D. Kharasch Nasal administration of opioids for pain management in adults Acta Anaesthesiol Scand 46 2002 759 770
11. H.W. Striebel, J. Kramer, and I. Luhmann [Pharmacokinetics of intranasal Fentanyl.] Schmerz 7 1993 122 125
12. S. Kaasa, K. Moksnes, and T. Nolte Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain J Opioid Manag 6 2010 17 26
13. D. Foster, R. Upton, L. Christrup, and L. Popper Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery Ann Pharmacother 42 2008 1380 1387
14. L.L. Christrup, D. Foster, and L.D. Popper Pharmacokinetics efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study Clin Ther 30 2008 469 481
15. H.G. Kress, A. Oronska, and Z. Kaczmarek Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period Clin Ther 31 2009 1177 1191
16. S. Mercadante, L. Radbruch, and A. Davies A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial Curr Med Res Opin 25 2009 2805 2815
17. N. Plock, A. Facius, and L. Hartmann An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects Int J Clin Pharmacol Ther 51 2013 495 508
18. J.T. Farrar, R.K. Portenoy, and J.A. Berlin Defining the clinically important difference in pain outcome measures Pain 88 2000 287 294
19. J.T. Farrar Advances in clinical research methodology for pain clinical trials Nat Med 16 2010 1284 1293
20. A. Davies, T. Sitte, and F. Elsner Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain J Pain Symptom Manage 41 2011 358 366
21. M. Fallon, C. Reale, and A. Davies Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study J Support Oncol 9 2011 224 231
22. R.K. Portenoy, A.W. Burton, N. Gabrail, and D. Taylor Fentanyl Pectin Nasal Spray 043 Study G. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain Pain 151 2010 617 624
23. L.R. Webster, K.A. Slevin, and A. Narayana Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes Pain Med 14 2013 1332 1345
24. R. Rauck, J. North, and L.N. Gever Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study Ann Oncol 21 2010 1308 1314
25. R.L. Rauck, M. Tark, and E. Reyes Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain Curr Med Res Opin 25 2009 2877 2885
26. R. Rauck, L. Reynolds, and J. Geach Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study Curr Med Res Opin 28 2012 859 870
27. D. Taylor, L. Radbruch, and J. Revnic A Report on the Long-term Use of Fentanyl Pectin Nasal Spray in Patients With Recurrent Breakthrough Pain J Pain Symptom Manage 47 2014 1001 1007
28. S. Nalamachu, D. Hassman, M.S. Wallace, and S. Dumble Derrick R, Howell J. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain Curr Med Res Opin 27 2011 519 530
29. N. Cherny, C. Ripamonti, and J. Pereira Strategies to manage the adverse effects of oral morphine: an evidence-based report J Clin Oncol 19 2001 2542 2554
30. L. Colloca, and F. Benedetti Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 6 2005 545 552